Magellan Stem Cells was delighted to take part in the AusBiotech International Conference 2025 in Melbourne where we showcased Magellan’s cell-manufacturing capabilities.
Across the four days of the conference, Magellan representatives engaged with hundreds of attendees and participants.
As one of the few Therapeutic Goods Administration-licenced GMP-certified CDMOs for cell therapies in Australia, Magellan has built a strong reputation in MSC cell manufacturing, supported by Phase III-ready facilities and robust GMP infrastructure.
Chief Medical Officer Associate Professor Dr Julien Freitag who greeted attendees at the booth said: “At Magellan we deliver end-to-end cell therapy support – from preclinical concept through to Phase III GMP manufacturing all delivered with the regulatory confidence, technical expertise, and collaborative approach needed to accelerate your therapy to market.”
Last year the Australian Federal Health Minister The Hon Mark Butler MP announced a $A7 million grant from Medical Research Future Fund towards Magellan’s Phase III trial.
It is pleasing to report that Magellan’s presence at the AusBiotech Conference was well received by all who visited our display.
Magellan sponsored – and our CMO Associate Professor Julen Freitag chaired – a session dedicated to cell and gene therapy development in the Asia Pacific Region.
Panel members included Simon Cool (SMART CRC ), Michelle Fraser (Revvity), Colin McLean (Cell Therapies Pty Ltd) and Greg Plunkett (Accelagen Pty Ltd ). They provided real world commentary on how the APAC region can actively promote and be involved in the development and clinical translation of cell and gene therapies to the bedside.
The conference is one of the pre-eminent life sciences conferences in the Asia-Pacific region and this year attracted more than 1600 delegates from more than 20 countries.
The conference was opened by Senator Michelle Ananda-Rajah who in her address to delegates highlighted the growing importance of the life sciences sector to Australia’s future innovation.
The Senator emphasised the remarkable capabilities of the nation’s health and medical innovators and the sector’s vital role in driving a more diversified and resilient Australian economy.
